Exchange: NASDAQ·Updated 07:37 PM EDT
News
all
press releases
SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’
Investors are now awaiting extra data from Sarepta’s mid-stage studies in two muscle diseases, facioscapulohumeral muscular dystrophy and myotonic dystrophy.
Stocktwits
More News
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.
Zacks
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.
Zacks
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (Sarepta or the Company).Sarepta is a biopharmaceutical company focused on...
Business Wire
Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated
SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.
Zacks
Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2026. As I begin my tenure as CEO, I am excited by the strength of Sarepta's foundation, the impact our therapies are having for patients...
Business Wire
ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously approved by its Board of Directors under Sareptas 2024 Employment Commencement Incentive Plan, as amended, as a material inducement to...
Business Wire

Advertisement|Remove ads.